Methylglyoxal-Derived Nucleoside Adducts Drive Vascular Dysfunction in a RAGE-Dependent Manner

Area of Science:

• Biochemistry
• Vascular Biology
• Diabetology

Background:

• Diabetic kidney disease (DKD) is a major cause of mortality in diabetic patients.
• Endothelial cell dysfunction (ECD) is an early indicator and exacerbating factor in DKD and vascular disease.
• Methylglyoxal (MG) adducts are known predictors of DKD risk in type 1 diabetes.

Purpose of the Study:

• To elucidate the mechanisms by which MG adducts contribute to vascular disease.
• To investigate the role of specific MG-induced nucleoside adducts (CEdG and CEG) in driving endothelial dysfunction.

Main Methods:

• Exposure of primary human umbilical vein endothelial cells (HUVECs) to CEdG and CEG.
• Assessment of endothelial dysfunction markers: monocyte adhesion, reactive oxygen species (ROS) production, and endothelial permeability.
• Transcriptomic analysis to identify dysfunctional signatures.
• Evaluation of the role of the receptor for advanced glycation end products (RAGE) signaling.

Main Results:

• CEdG and CEG exposure induced significant endothelial dysfunction in HUVECs.
• Dysfunctional phenotypes included increased monocyte adhesion, elevated ROS production, enhanced permeability, and impaired homeostasis.
• A dysfunctional transcriptomic signature was observed.
• Inhibition of intracellular RAGE signaling attenuated these detrimental effects.

Conclusions:

• MG-induced nucleoside adducts (CEdG and CEG) actively drive endothelial dysfunction.
• These adducts operate through RAGE signaling pathways.
• MG adducts are not only biomarkers but also potential causative agents in vascular disease progression, presenting novel therapeutic opportunities.